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ABSTRACT
Objectives: Delayed or insufficient breast milk production, as well as low milk supply, is still a challenging problem to 
overcome, particularly in the case of preterm delivery. Herbal galactagogues might be a good way to increase milk supply, 
however, there is a lack of clinical studies confirming their efficacy and safety.
The aim of this study was to verify the safety and effectiveness as a galactagogue of the unique galactagogue composition 
based on barley malt with β -glucan and lemon balm.
Material and methods: The study included 117 mothers of preterm infants randomly divided into the Galactagogue 
Group given galactagogue and the Placebo Group. A complete data set was obtained for 80 participants, divided equally 
between two groups.
Volume of milk expressed by mothers during the first two weeks after delivery was the primary outcome and safety  
of the product was the secondary outcome. 
Results: Volume of milk recorded on participants’ last visit in the Galactagogue Group was significantly higher than in the  
Placebo Group (95 mL  vs 62.5 mL, p = 0.049). The total expressed milk volume during the study was 4209 ± 335 mL  
in the Placebo Group  vs 6036 ± 498 mL (p = 0.003) in the Galactagogue Group.
Conclusions: Supplementation with unique Galactagogue composition was safe and increased milk output which allowed 
achieving target minimal volume of 500 mL per day in first week of lactation in preterm mothers. 
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INTRODUCTION 
Lactogenesis in humans is a very complicated process. 
It depends not only on reproductive and metabolic hor-
mones but is self-regulated through the autocrine-paracrine 
mechanism. Additionally, both physical and emotional fac-
tors are involved in successful onset of milk production [1–4]. 
The fall of progesterone after delivery, followed by increase 
in prolactin (PRL) levels triggers the beginning of lactogenesis 
II, a period of copious milk secretion. However, there is no 
direct correlation between baseline PRL levels and volume 
of expressed milk [5]. Milk volume depends mostly on fre-
quency and duration of breastfeeding/pumping throughout 
early lactation period [5]. 
Delayed or insufficient breast milk production, as well as 
low milk supply, is still a challenging problem to overcome, 
particularly in the case of preterm delivery [6–8] which re-
sults in lower basal PRL levels compared with mothers who 
give birth at term [9]. The other non-physiological causes of 
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lactational failure are complex and include separation from 
the newborn after delivery, poor maternal psychological 
well-being and health after an unexpected delivery [10–13]. 
For vulnerable preterm infants, a mother’s own milk 
is more a medicine than nutrition. The mother’s milk in-
take is increasingly recognized as a key variable associated 
with positive clinical outcomes in preterm infants [14–16]. 
Therefore, it is reasonable to seek new, natural substances 
which act as a galactagogues) initiating and augmenting 
the secretion of mother’s milk [17]. Unfortunately, earlier 
studies with herbal based galactagogues have not been 
well-designed because of a lack of randomization, controls 
or blinding and with poor evidence regarding the efficacy 
and safety [18–20]. A good candidate for natural and safe 
galactagogue may be ß-glucan present in barley malt.
Barley malt is produced from the malting process where 
grains are allowed to germinate and then quickly dried. 
As a result of malting, bioactive components including those 
that potentially increase milk supply, are released from bar-
ley grain [21]. In fact, non-alcoholic beer is used traditionally 
by mothers in many cultures during lactation to increase 
milk supply although its prolactogenic mechanism has not 
been fully clarified with a clinical study [22, 23]. 
Studies based on animal models suggests that a poly-
saccharide such as β-glucan found in barley enables milk 
production by prolactin dependent mechanisms after intra-
venous injection [24, 25]. An observational study was con-
ducted in group of 128 mothers with insufficient milk supply 
who consumed barley malt-based product for 14 days [26]. 
Certified lactation consultants evaluated time of effective 
sucking and other factors responsible for a successful lacta-
tion. Regular breast milk swallowing was elongated in 91% 
of babies and the amount of milk pumped by mothers in-
creased more than twice [26]. Therefore, the beneficial effect 
of the formulation based on barley malt with β -glucan and 
lemon balm (Galactogogue) was investigated further in the 
group of mothers who gave birth prematurely and were 
vulnerable to lactation failure. 
Objectives
The aim of this double-blind, randomized, placebo con-
trolled study was to investigate efficacy in increasing milk pro-
duction and safety of use of unique galactagogue composition.
MATERIAL AND METHODS 
Settings and Participants
This study was conducted at two NICUs associated with 
the Medical University of Warsaw between April 2014 and 
October 2015 with approval of the Ethics Committee 
in the Medical University of Warsaw (number KB 40/2014). 
The target population consisted of women above 18 years 
old who delivered infants < 37 weeks gestation (gestational 
age confirmed according to the last menstrual period) and 
gave written informed consent to participate in the study.
Participants were eligible for the study if they were 
available to be enrolled within two days following birth, 
declaredelectric breast pump use (at least 6 times a day, 
including night) and agreed on filling up the lactation diary 
which allowed to monitor the increase in expressed milk 
volume through the progress of establishing and maintain-
ing lactation. Women were considered ineligible if they 
were diagnosed with hypothyroidism or either type 1 or 
2 diabetes before pregnancy and were receiving treatment. 
Moreover, participants already participating in another clini-
cal trial were excluded.
This RCT was retrospectively registered on ClinicalTri-
als.gov on November 14th, 2017 under the identification 
number NCT03341481.
Study Design
This clinical trial was double-blind, randomized, and pla-
cebo-controlled, conducted according to the Good Clinical 
Practice, including monitoring by a qualified Clinical Re-
search Associate. One Hundred Seventeen mothers who 
gave birth prematurely were enrolled in the study within 
48 hours postpartum and were randomly assigned to the 
two study groups (Placebo Group or Galactagogue Group). 
The concealed allocation sequence was generated by central 
randomization using a computer software program. Femalt-
iker® a proprietary, commercially available product produced 
by Nutropharma Llc., was used as the galactagogue in the 
Galactagogue Group. Femaltiker® containing composition 
was notified at the Polish Chief Sanitary Inspectorate as food 
for special medical purposes. Femaltiker formula consists of 
powdered lemon balm leaves (Melissa officinalis L.); barley 
malt (Hordeum vulgare Linn) enriched with 70% barley-glu-
can. Other inactive ingredients included sucrose and natural 
caramel flavoring. The composition is protected by patent 
nr. 229569, therefore the exact amount of each component 
was not disclosed. The placebo was produced as a blend 
of sucrose, apple fiber and natural aroma caramel and was 
in the same package as Femaltker®. The products were in-
distinguishable by color, taste and texture. Each subject 
received 28 packages to take twice daily for 14 days dur-
ing the study. Participants were asked to return the empty 
packages during their check-up for compliance monitoring. 
Participants and medical staff were blinded to which pack-
age contained the active product until the end of the trial.
According to the study scheme mothers had to have 
undergone three hospital visits during the first two weeks 
postpartum. The first visit occurred as soon as possible, 
following delivery but no later than on the second day 
(± 1 day) post-delivery. The second visit occurred at the end 
of the first week of lactation at day six and the third visit was 
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on day 14 (± 2 days) postpartum. Mothers were instructed 
to pump their breasts every four hours (six times per day 
for 10–15 minutes per breast) using a standardized electric 
breast pump. A Symphony® PLUSTM Breast Pump, Medela, 
Switzerland was used in the hospital and a Lactina Electric® 
PLUSTM Medela, Switzerland was available for home use. 
Primary and secondary outcomes
The primary outcome was the total volume of milk ex-
pressed by participants from the second to the 14th postnatal 
day. Secondary outcome was the safety of the intervention.
Data collection
Clinical data of mothers and infants at delivery and 
throughout study duration were collected including ma-
ternal and infant demographics, prior breastfeeding expe-
rience, colostrum expression after delivery and ability to 
latch onto the breast. 
Milk production data
Participants recorded daily lactation information during 
the study including exact volume of milk in mL expressed at 
each expression session, the exact time of each milk expres-
sion session, the total milk expression time per day, the total 
amount of milk expressed per day, and the longest interval 
between expression sessions in a standardized lactation diary. 
Information concerning self-estimation of the onset of lac-
togenesis stage II was provided by participants marking the 
applicable answer in the lactation diary (feeling of full/empty 
breasts, swollen, painful, tender). The lactation diary and 
lactation equipment including Medela’s 150 mL disposable 
bottles were provided to participants at the study enrollment. 
Daily volume of milk produced was confirmed by 
the medical staff by summation of all recorded milk volumes 
during a 24-hour period prior each of hospital visits. Fur-
thermore, the amount of milk expressed in a single session 
during each hospital visit on days 2 (+/1 day), 6, 14 (+/2 days) 
postpartum was measured using Medela’s 150 mL dispos-
able bottles by the lactation consultant.
Safety data
Possible side effects of the intervention were monitored 
at each visit by a member of the clinical team. It included 
skin examination and collecting information from subjects 
concerning digestive symptoms such as nausea, a bad taste 
in the mouth, and pain. If side effects occurred, they were 
assessed by completing a rating scale of adverse symptoms 
intensity (mild, moderate, severe).
Data analysis and statistical tests
Data analysis included only those subjects who com-
pleted the study per protocol. 
Study sample was calculated based on previous re-
search. It was assumed that the standard deviation (SD) of 
the mean milk production in the second week of lactation 
is approximately 160 mL/day [27]. Therefore, we expected 
a SD of total breast milk volume of about 2500 mL within 
the first 14 days postpartum. Under further assumptions 
of statistical significance level of p < 0.5 and power of 0.8, 
we calculated that with a sample size of 40 participants 
per group it would be possible to assess (using standard 
t-test) a difference between study groups of size 1585 mL 
as statistically significant. A full data set was obtained for 
80 participants, divided equally between the two study 
groups. The data was imported into SPSS for Windows for 
further analysis. 
Student t-test for independent sample was used to 
analyze demographic variables including mother’s age at 
the time of delivery, duration of pregnancy (in multiple 
pregnancies), infant gestational age and birth weight. They 
were compared using 95% confidence intervals for means 
with standard error (SE). 
Moreover, maternal factors related to pregnancy and 
postnatal care were compared using χ2 testing. Student 
t-test was used to compare lactation stimulation parameters 
as total volume of expressed milk, total time of expressing, 
number of expression sessions between groups. There were 
showed using 95% confidence intervals for means with SE. 
Difference in daily volume of milk in the following days was 
presented using 95% confidence intervals for means with 
SE. Volume of milk from day 4 to 11 depending on the study 
group was analyzed by variance analysis (ANOVA). The daily 
volume of expressed milk was only analyzed for the time in 
which all 80 subjects participated in the study (to the 11th 
day postpartum) and the volume of expressed milk was 
measurable in mL (volume ≥ 1 mL from 4th day postpartum). 
Additionally, covariance analysis (ANCOVA) was per-
formed with Placebo Group  vs Galactagogue Group as 
grouping variable and number of the sessions during the 
day as a covariant.
A p-value of < .05 was considered statistically significant, 
p <. 01 was considered highly significant.
RESULTS
One hundred seventeen mothers of preterm infants 
were randomized with 59 allocated to the placebo and 58 to 
the Galactagogue group. Four participants from each group 
did not receive the intervention. Reasons for not receiv-
ing the intervention, loss to follow-up and exclusion from 
analysis are listed on Figure 1. Complete data was obtained 
for 40 participants in each arm. 
There was no statistically significant difference be-
tween participants in terms of demographic characteristics. 
In addition, there were no statistically significant differ-
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ences in their infant’s birth weight or gestational age (Tab. 
1). Finally, there was no significant difference in pregnancy 
and postnatal care in both groups. Participants were mostly 
primiparas that gave singleton birth through caesarian sec-
tion with no previous breastfeeding experience (data not 
shown). Colostrum expression was possible in 39 women 
(97.5%) from Placebo Group and 37 women (92.5%) in the 
Galactagogue Group (χ2 = 1.05; p = 0.30). Due to prema-
ture birth a low number of neonates were able to latch on 
instantly 5 (12.5%) in the Placebo Group and 7 (17.5%) in 
the Galactagogue Group; χ2 = 0.32; p = 0.53). 
Milk production data
Volume of milk expressed during the three hospital visits 
is presented as the median with 95% CI in Figure 2. Volume 
expressed during the third visit (day 14) was statistically 
significantly higher in mothers who received Galactagogue 
compared to the Placebo Group (62.5 mL  vs 95 mL; Z = 2.40, 
p = 0.01, with Bonferrroni correction p = 0.049).
Total volume of milk recorded in the lactation diaries 
over the entire study from day 2 to 14 was statistically 
significantly higher in the group receiving Galactagogue 
(6036 mL ± 498 vs 4209 mL ± 335; p = 0.003). There were 
Figure 1. Flow Chart of Study; The blue boxes show the progress through the phases of a parallel randomized trial of two groups: Galactagogue 
and Placebo. Numbers in white boxes (n) show the subjects excluded, withdrawn from the study, patients that dropped off and number of subjects 
taken for analysis
Table 1. Mothers (n = 80) and infants (n = 114) characteristics at randomization 
Mothers
Placebo group (n = 40) Galactagogue group (n = 40)
t p
M ± SE 95% CI M ± SE 95% CI
Age [years] 31.6 ± 0.8 30.0–33.1 30.9 ± 0.8 29.3–32.5 0.63 0.53
Pregnancy week at birth 31.5 ± 0.4 30.6–32.4 31.5 ± 0.5 30.4–32.8 0.00 1.00
Infants
Placebo Group (n = 56) Galactagogue Group (n = 58)
t p
M ± SE 95% CI M ± SE 95% CI
Birth weight 1719 ± 100 1553–1885 1745 ± 92 1589–1900 0.19 0.85
Gestational age [weeks] 31.4 ± 0.4 30.7–32.2 31.8 ± 0.5 31.0–32.7 0.60 0.55
Demographics of participants in analyzed sample n (80) of mothers and infants n (114); The difference with p value < 0.05 is considered statistically significant; M — mean; 
SE — standard error; CI —confidence interval
122
Ginekologia Polska 2021, vol. 92, no. 2
www. journals.viamedica.pl/ginekologia_polska
no differences in the total expression time (p = 0.68) 
and number of milk expression sessions (p = 0.27) between 
the study groups (Tab. 2). Despite the exemptions from the 
protocol regarding the interval between follow-up visits in 
case of four participants, the mean period of participation in 
the study did not differ between groups (p = 0.40) (Tab. 2).
Comparison of the average daily volume of milk ex-
pressed revealed that the Galactagogue Group expressed 
statistically more milk already on day seven of the study 
(p = 0.01). The Placebo Group failed to reach 500 mL of 
expressed milk per day throughout whole study period 
(Fig. 3, Tab. 3). 
A statistically significant effect of the group was found 
on daily volume of milk (F = 5.91, p = 0.017). The daily volume 
of milk was statistically significantly higher in the Galacta-
gogue Group throughout the study period in comparison 
to the Placebo Group. Only on 4 day (p = 0.13) and 6 day 
(p = 0.05) of the study the results failed to show statistical 
significance (Tab. 3).
The analysis with a number of milk expressing sessions 
during particular day as a covariant has shown differences in 
daily milk volume between the study groups. In the Galac-
tagogue Group on days from 7 to 11 of the study there was 
statistically significantly (p < 0.05 for group factor) higher 
milk production in comparison to the Placebo Group (Tab. 4). 
On Days 9 and 10 the daily number of sessions had shown 
significant influence on the milk production in the study 
groups (p = 0.009 and p = 0.04, respectively). This factor 
(daily number of sessions) has been included in the results 
and despite it the experimental group still obtained higher 
results for milk volume than the Placebo Group (Tab. 4). 
Safety data
During the verbal assessment of intervention safety, two 
affirmative answers were noted in the placebo group, one was 
qualified as a serious side effect (SAE) not related to the prod-
uct taken. Reported dryness of the skin was assumed to be 
related to iatrogenic hyperchloremia caused by administrated 
intravenous fluids and the participant was withdrawn from 
the study. There were no side effects reported in the group 
receiving Galactagogue. The product was well tolerated and 
consumed as a drink by a majority of the participants. One 
subject in the Placebo group reported the compound tasted 
bad and was withdrawn from the study.
DISCUSSION
This study suggests that Galactagogue which is com-
posed of barley malt, β-glucan and lemon balm can serve as 
a galactagogue in mothers of preterm infants who struggle 
with insufficient milk production. Our study revealed that 
dietary intervention supplementation with food for special 
medical purposes Femaltiker® during the first two weeks 
of lactation increased milk volume in mothers of prema-
ture infants. Compared to the Placebo Group, mothers 
who received the Galactagogue composition produced 
34% more milk during session on day 14 of lactation. Data 
obtained from the lactation diaries were consistent with 
data obtained by lactation consultations at the hospital. 
The Galactagogue Group produced 30% more milk during 
the whole study period that was taken into the consider-
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Figure 2. The volume of expressed mother’s milk recorded at the 
hospital visit; The median milk volume expressed by women in the study 
groups (blue — placebo group, dark grey — galactagogue group) in the 
subsequent three measurement sessions at the hospital visit. The error 
bars represent 95% CI. The asterisks indicate result that differ statistically 
significantly with p-value < 0.05
Table 2. Total volume of expressed milk, total time of expressing and total number of expression sessions, duration of the study (n = 80) 
Placebo group (n = 40) Galactagogue group (n = 40)
t p
M ± SE 95% CI M ± SE 95% CI
The volume of expressed 
breastmilk [mL] 4209 ± 335 3531–4886 6036 ± 498 5029–7043 3.04 0.003
Total expression time [min] 2211 ± 114 1980–2442 2280 ± 123 2031–2530 0.41 0.68
Number of expression 
sessions [n] 82 ± 2 78–86 85 ± 2 81–90 1.11 0.27
Duration of the study [days] 12 ± 0.2 11.3–12.2 12±0.2 11.6–12.3 0.84 0.40
Indicators related to stimulation of lactation for analyzed sample (n = 80); The difference with p value < 0.05 is considered statistically significant; M — mean; SE — standard 
error; CI —confidence interval
123
Aleksandra Wesolowska et al., Barley malt-based composition as a galactagogue 
www. journals.viamedica.pl/ginekologia_polska
Increases in milk volume were not associated with maternal 
factors, postnatal care, or lactation practices recognized as 
supportive to milk supply in mothers of preterm infants. 
Perceived and real insufficient milk supply is the most 
common reason for formula introduction in the early neona-
tal period [28, 29]. It is especially harmful for preterm infants 
for whom mother’s milk is crucial for their development 
and health [30, 31]. Unfortunately, mothers of preterm in-
fants are at high risk of breastfeeding difficulties and the 
reasons for this are complex [32]. Often, regular milk expres-
sion, family support and medical advice including lactation 
consultation fail to resolve the problem [10, 15, 33] and ma-
ternal treatment to increase milk supply may be important. 
It is noteworthy that in Poland drugs such as domperidone 
and metoclopramide, that have proven efficacy in increasing 
milk production are not authorized for this indication, there-
fore their use is treated as off- label use [17] and is rather 
marginal. Other popular herbal galactagogues such as fenu-
greek and silymarin from milk thistle (Silybum marianum) 
does not have strong and consistent scientific evidence in 
milk increase [17]. Fenugreek should be used with caution 
due to its unclear safety profile and very mild effect on milk 
production in studies with likely a placebo effect [17, 34]. 
One of the first randomized controlled trial (RCT) aimed 
to evaluate the efficacy of silymarin in mothers of preterm in-
fants did not show statistically significant differences in milk 
production. When the formulation was improved by adding 
components to increase absorption, lactogenic effects were 
observed in the first month of lactation which continued 
over the first 3 months [35, 36]. The total average milk volume 
observed in both groups by Zecca et al. [35], (4136 ± 4093 mL 
in the placebo vs 6523 ± 5298 mL in the experimental, 
p < 0.02) was comparable to our study (4208.8 ± 335.04 mL, 
in the Placebo Group  vs 6035.9 ± 497.80 in Galactagogue 
Group , p = 0.0033). However, in our study the result spread 
between the patients was less by order of magnitude and 
intervention time was two times shorter (30 days of supple-
mentation versus 14 days). 
It is noteworthy that mothers in the experimental group 
in our study achieved an average daily expressed volume 
of milk of more than 500 mL/d on day seven in comparison 
to the Placebo Group where this amount of milk was not 
achieved even at the last day of the study (Fig. 3, Tab. 3). 
As was shown earlier milk volume in the early stage of 
lactation is a predictor of successful milk production after 
very preterm birth [11, 37]. Evidence indicates that the first 
14 days is a critical period for coming into the volume. Milk 
supply greater than 500 mL/d is a predictor of infants receiv-
ing maternal milk at discharge [33, 38].
To reflect the demands of a breastfed term baby recom-
mendation for expression frequency is 8–12 times per day in-
cluding during the night [39, 40, 41]. However, this frequency 
is not always achieved which may affect the quantity of milk 
produced [42]. Our study revealed that the overall mean num-
ber of daily expression sessions was seven times per day. 
Because expression frequency can impact milk production, 
daily volume of milk from day 7 to 11 were controlled for 
number of expression sessions in consecutive days by cova-
riance analysis. Even though differences in milk expression 
frequency were observed between groups in selected study 
days (days 9 and 10), the daily volume of milk in the Galacta-
gogue Group was still statistically significantly higher from 
day 7 to day 11 in comparison to the Placebo Group (Tab. 4). 
Barley malt-based product was mentioned as a lactation 
stimulant and included as a part of lactation consultation 
scheme in case of insufficient milk supply [43]. The Expert’s 
Figure 3. The average daily volume of mother’s milk expressed by participants in the course of study; Mean milk volume expressed from day 4 to 11 
in the Galactagogue Group (dark grey line) and the Placebo Group (light grey line). The error bars represent Standard Error (SE), The asterisks indicate 
result that differ statistically significantly with  p-value < 0.05
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Table 3. Daily volume of milk in consecutive days
Volume of milk
Day Mean nr. of  sessions
Placebo  
Group (n = 40)
Galactagogue
Group (n = 40)







M ± SE 149.3 ± 23.5 203.4 ± 26.7
0.13
95% CI 101.6–196.9 149.3–257.5
5th 7
M ± SE 233.4 ± 23.5 333.3 ± 35.9
0.02 F
1 = 5.91
p1 = 0.01795% CI 185.9–280.9 260.8–405.9
6th 7
M ± SE 325.9 ± 28.8 424.6 ± 41.8
0.05
95% CI 267.7–384.2 340.1–606.2
7th 7
M ± SE 359.5 ± 29.7 508.6 ± 48.2
0.01 F
2 = 135.83
p2 < 0.000195% CI 299.4–419.6 411.0–606.2
8th 7
M ± SE 398.9 ± 32.0 556.4 ± 50.6
0.01
95% CI 334.2–463.6 454.0–658.9
9th 7
M ± SE 421.4 ± 34.1 594.3 ± 54.0
0.008 F
3 = 3.12
P3 = 0.003195% CI 352.5–490.4 485.0–703.6
10th 8
M ± SE 449.7 ± 34.4 579.5 ± 48.0
0.03
95% CI 380.1–519.4 482.6–676.9
11th 7
M ± SE 469.2 ± 37.9 605.8 ± 52.4
0.03
95% CI 392.5–545.8 499.8–711.8
M — mean; SE — standard error; CI —confidence interval; The daily volume of milk and number of expression sessions in consecutive days from 4 to 11 was indicated as 
a M with SE and 95% CI. The difference with p value < 0.05 is considered statistically significant
Group recommendations of the Dietary Guidelines for lac-
tating women put barley malt product use as an example of 
good dietary praxis supporting lactation process in women 
[44]. Authors emphasized that barley malt and its active 
constituent - β-glucan are safe for use. Although allergy to 
barley is rare, individuals suffering from celiac disease should 
eliminate barley from their diet because it contains gluten. 
In our study safety data were collected and we showed that 
consumption of Femaltiker® which contains Galactagogue 
composition of barley malt with β-glucan and lemon balm 
did not cause any adverse reactions in mothers throughout 
study period. 
CONCLUSIONS
Galactagogue composition, based on barley malt is 
safe and increases milk production in mothers of preterm 
infants. 
We conclude that unique patented galactagogue for-
mula can be safely administered in the first two weeks of 
lactation but the effect of the intervention on maintaining 
milk supply needs to be evaluated in the future studies.
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